TERN - NASDAQ
Terns Pharmaceuticals, Inc.
$52.95
+0.0000%Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
At a Glance
Live SnapshotTerns Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Terns Pharmaceuticals, Inc. Balance Sheet
TERN • NASDAQ
| Terns Pharmaceuticals, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
524.7M | 161.4M | 79.9M | 143.2M | 47.7M | 74.9M | 12.3M | 82.5M | |
494.2M | 196.7M | 183.5M | 139.9M | 118.3M | 0.0 | 7.3M | 4.4M | |
1B | 358.2M | 263.4M | 283.1M | 166M | 74.9M | 19.7M | 86.9M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.7M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.7M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 948K | 1.2M | 2.1M | 1.4M | |
5.2M | 3.9M | 4M | 2.1M | 0.0 | 2.1M | 461K | 162K | |
1B | 362.1M | 267.4M | 285.2M | 166.9M | 90.9M | 22.2M | 88.5M | |
NON-CURRENT ASSETS | ||||||||
884K | 1.5M | 1M | 1.8M | 1M | 1.2M | 961K | 261K | |
0.0 | 350K | 56K | 37K | 94K | 246K | 719K | 335K | |
884K | 1.8M | 1.1M | 1.8M | 1.1M | 1.4M | 1.7M | 596K | |
1B | 363.9M | 268.5M | 287M | 168.1M | 92.3M | 23.9M | 89.1M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
1.7M | 2.1M | 2.5M | 1.6M | 2.1M | 935K | 1.6M | 914K | |
1.7M | 2.1M | 2.5M | 1.6M | 2.1M | 935K | 1.6M | 914K | |
6.9M | 4.7M | 2.9M | 6M | 4.3M | 1.5M | 1.2M | 1.3M | |
0.0 | 428K | 0.0 | 0.0 | 0.0 | 12.9M | 0.0 | 0.0 | |
474K | 0.0 | 603K | 661K | 0.0 | 0.0 | 0.0 | 0.0 | |
1.7M | 1.5M | 1.2M | 1.1M | 0.0 | 657K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 836K | 0.0 | 0.0 | |
7.4M | 8.4M | 6M | 185K | 358K | 6.7M | 2.1M | 127K | |
16.4M | 15.7M | 11.9M | 8.5M | 6.8M | 22.8M | 5M | 2.4M | |
NON-CURRENT LIABILITIES | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 345K | 142K | |
1.7M | 1.5M | 1.2M | 1.1M | 947K | 877K | 285K | 14.3M | |
2.1M | 2.4M | 1.2M | 1.6M | 947K | 877K | 630K | 14.5M | |
919K | 919K | 603K | 1.2M | 0.0 | 0.0 | 0.0 | 0.0 | |
18.6M | 18.1M | 13.2M | 10.1M | 7.8M | 23.7M | 5.6M | 16.8M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 186M | 95M | 95M | |
11K | 9K | 6K | 5K | 3K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 588M | 520.2M | 342.7M | 14.6M | 1.2M | 455K | |
-517.7M | -421.5M | -332.6M | -242.4M | -182.1M | -131.9M | -91.9M | -23.3M | |
260K | -279K | -19K | -822K | -338K | -124K | -106K | 59K | |
1.5B | 767.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1B | 345.9M | 255.4M | 276.9M | 160.3M | 68.6M | 4.2M | 72.2M | |
1B | 345.9M | 255.4M | 276.9M | 160.3M | 68.6M | 18.3M | 86.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.1M | 14.3M | |
SUMMARY | ||||||||
1B | 363.9M | 268.5M | 287M | 168.1M | 92.3M | 23.9M | 89.1M | |
494.2M | 196.7M | 183.5M | 139.9M | 118.3M | 0.0 | 7.3M | 4.4M | |
919K | 1.3M | 603K | 1.2M | 0.0 | 12.9M | 0.0 | 0.0 | |
-523.8M | -160.1M | -79.3M | -142M | -47.7M | -62M | -12.3M | -82.5M | |
90,077,698 | 90,077,698 | 90,077,698 | 90,077,698 | 90,077,698 | 90,077,698 | 90,077,698 | 90,077,698 |
SEC Filings
TERN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 22, 2026 | January 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 11, 2025 | December 09, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your TERN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.